Circulating Angiogenic Factors and Preeclampsia

Tsatsaris,; Goffin, Frédéric; Jm, Foidart

doi:10.1056/nejm200405063501918

Cited by 18 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, decreased levels of free serum VEGF and PlGF were found in patients with PE compared to normal controls, which was proportionate to the rise in serum sFlt1 levels in these patients ( 38 ). Another two studies demonstrated significantly higher serum levels of sFlt-1 (an almost 6-fold increase) and lower free PlGF levels in women with PE than those from non-pregnant women ( 16 , 17 ).…”

Section: Plgf and Sflt-1 In Pementioning

confidence: 95%

Predictive value of the sFlt‑1/PlGF ratio in women with suspected preeclampsia: An update (Review)

et al. 2023

View full text Add to dashboard Cite

Preeclampsia (PE) is a major complication of pregnancy with an incidence rate of 2-8% and is a leading cause of maternal mortality and morbidity. The various consequences of severe preeclampsia for the fetus, neonate and child include intrauterine growth retardation (IUGR), fetal hypoxia, oligohydramnios, intrauterine fetal demise, increased perinatal mortality and morbidity, neurodevelopmental disorders and even irreversible brain damage (cerebral palsy). A number of studies have demonstrated that differences in maternal serum concentrations of angiogenic factors between preeclampsia and normotensive pregnancies can be used as biomarkers, either alone or in combination with other markers, to predict the development of PE. The presence in the maternal circulation of two proteins of placental origin, placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1), has been shown to be of clinical value, as the sFlt-1/PlGF ratio appears to be the optimal predictive tool for the development of PE. The measurement of their concentration in maternal serum in screening models, serves as predictive marker for the development of PE or IUGR later in gestation. However, further research is required to improve its clinical applicability and provide guidelines for its use worldwide to achieve more consistent clinical management of women with PE.

show abstract

Section: Plgf and Sflt-1 In Pementioning

confidence: 95%

Predictive value of the sFlt‑1/PlGF ratio in women with suspected preeclampsia: An update (Review)

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Abnormal placental angiogenesis is associated with pre‐eclampsia. 190 Pre‐eclampsia is a pregnancy‐related vascular disease and is the leading cause of maternal and foetal morbidity and mortality. Before the onset of pre‐eclampsia, the circulating levels of soluble endoglin (sEng) and soluble FMS‐like tyrosine kinase‐1 (sFlt‐1) are increased, and then VEGF and placental growth factor are decreased, thus leading to pre‐eclampsia.…”

Section: The Role Of H 2 S ...mentioning

confidence: 99%

Role of hydrogen sulphide in physiological and pathological angiogenesis

et al. 2022

View full text Add to dashboard Cite

The role of hydrogen sulphide (H2S) in angiogenesis has been widely demonstrated. Vascular endothelial growth factor (VEGF) plays an important role in H2S‐induced angiogenesis. H2S promotes angiogenesis by upregulating VEGF via pro‐angiogenic signal transduction. The involved signalling pathways include the mitogen‐activated protein kinase pathway, phosphoinositide‐3 kinase pathway, nitric oxide (NO) synthase/NO pathway, signal transducer and activator of transcription 3 (STAT3) pathway, and adenosine triphosphate (ATP)‐sensitive potassium (KATP) channels. H2S has been shown to contribute to tumour angiogenesis, diabetic wound healing, angiogenesis in cardiac and cerebral ischaemic tissues, and physiological angiogenesis during the menstrual cycle and pregnancy. Furthermore, H2S can exert an anti‐angiogenic effect by inactivating Wnt/β‐catenin signalling or blocking the STAT3 pathway in tumours. Therefore, H2S plays a double‐edged sword role in the process of angiogenesis. The regulation of H2S production is a promising therapeutic approach for angiogenesis‐associated diseases. Novel H2S donors and/or inhibitors can be developed in the treatment of angiogenesis‐dependent diseases.

show abstract